The use of an implantable cyclosporine a delivery system for preventing corneal allograft rejection in patients with alkali-burned corneas

Ophthalmic Practice

Volumn 20, Issue 8, 2002, Pages 302-306

  Xie, Lixin ^a   Shi, Weiyun ^a   Li, Shaowei ^a   Zeng, Qingyan ^a  

^a SHANDONG EYE INSTITUTE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALI; CYCLOSPORIN A; POLYGLACTIN;

ADULT; ANTERIOR EYE CHAMBER; ARTICLE; CASE REPORT; CELL DENSITY; CELL LOSS; CORNEA BURN; CORNEA PERFORATION; CORNEA TRANSPLANTATION; CORNEA VASCULARIZATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG IMPLANT; DRUG SAFETY; ENDOTHELIUM CELL; EYE TOXICITY; FEMALE; FOLLOW UP; GRAFT REJECTION; HIGH RISK PATIENT; HUMAN; INTRAOPERATIVE PERIOD; KERATOPLASTY; MALE; PATIENT COMPLIANCE; SPECULAR MICROSCOPY;

EID: 0036816844     PISSN: 08329869     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (14)

1. Carpenter CB. Immunosuppression in organ transplantation. N Engl J Med 1990; 322: 1224-1226.
2. The U.S. Multicenter FK506 Liver Society Group. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression in liver transplantation. N Engl J Med 1994; 331: 1110-1155.
3. De Rojas Silva MV, Rodriguez-Ares MT, Sanchez-Salorio M, et al. Efficacy of subconjunctival cyclosporine-containing microspheres on keratoplasty rejection in the rabbit. Grafe's Arch Clin Exp Ophthalmol 1999; 237: 840-847.
4. Xie L, Shi W, Wang Z, et al. Prolongation of corneal allograft survival using cyclosporine in a polylactideco-glycolide polymer. Cornea 2001; 20: 748-752.
5. Hirst LW, Lee GA. Corneal scleral transplantation for end stage corneal disease. Br J Ophthalmol 1998; 82: 1276-1279.
6. Oh C, Apel AJG, Saville BA, et al. Local efficacy of cyclosporine in corneal transplant therapy. Curr Eye Res 1994; 13: 337-343.
7. Kahan BD. Cyclosporine: The agent and its actions. Transplant Proc 1985; 17: 5-32.
8. Apel A, Oh C, Chiu R, et al. A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy. Curr Eye Res 1995; 14: 659-677.
9. Chen YF, Gebhardt RM, Reidy JJ, et al. Cyclosporinecontaining collagen shields suppress corneal allograft rejection. Am J Ophthalmol 1990; 109: 132-137.
10. Rehany U, Waisman M. Suppression of corneal allograft rejection by systemic cyclosporine A in heavily vascularized rabbit corneas following alkali bums. Cornea 1994; 13: 447-453.
11. Hill JC. Systemic cyclosporine in high-risk keratoplasty short- versus long-term therapy. Ophthalmology 1994; 101: 128-133.
12. Kahan BD. Solid organ transplantation. Immunologic theory and immunosuppressive strategy. Immunol Allergy Clin N Am 1996; 16: 221-242.
13. Newton C, Gebhardt BM, Kaufman HE. Topically applied cyclosporine in azone prolongs corneal allograft survival. Invest Ophthalmol Vis Sci 1988; 29: 208-215.
14. Salisbury JD, Gebhardt BM. Suppression of corneal allograft rejection by cyclosporine A. Arch Ophthalmol 1981; 99: 1640-1643.